866-997-4948(US-Canada Toll Free)

Type 2 Diabetes - Global Drug Forecasts and Treatment Analysis to 2020

Published By :

GlobalData

Published Date : Feb 2012

Category :

Diabetes

No. of Pages : 517 Pages


GlobalData, the industry analysis specialist, has released its new report, Type 2 Diabetes - Global Drug Forecasts and Treatment Analysis to 2020. The report is an essential source of information and analysis on the global type 2 diabetes therapeutics market. The report provides comprehensive information on type 2 diabetes, highlighting the treatment guidelines. It identifies and analyses the key trends shaping and driving the global type 2 diabetes therapeutics market. It analyses the treatment usage patterns in the global type 2 diabetes therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global type 2 diabetes sector. It quantifies the unmet need in the global type 2 diabetes therapeutics market as well as in the individual markets such as the US and the top five countries in Europe, highlighting the opportunity for future players.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts.

GlobalData analysis shows that the global type 2 diabetes therapeutics market was worth $23.7 billion in 2011. Between 2002 and 2011, the market grew at a rate of 11.8%. By 2020, the market is expected to be worth $45.1 billion, indicating a Compound Annual Growth Rate (CAGR) of 7.4% between 2011 and 2020.

The global type 2 diabetes therapeutics market is very attractive and has primarily been driven by the growth in patient volume and the annual cost of therapy. Patient volume has been driven by the increased incidence and prevalence of diabetes and the growth in treatment usage patterns, such as the diseased population, the treatment-seeking population, the diagnosed population and the prescription population. The annual cost of type 2 diabetes therapy was driven by the uptake of newly approved drugs, such as Actos (pioglitazone) and Avandia (rosiglitazone) until 2006 and the launch of new therapies, such as Levemir (insulin detemir), Byetta (exenatide), Januvia (sitagliptin), and Victoza (liraglutide). The annual cost of therapy was also driven by the increased use of multiple drugs per patient and the adoption of combination therapies, such as Actoplusmet (pioglitazone and metformin), Avandamet (rosiglitazone and metformin), Janumet (sitagliptin and metformin) and Duetact (pioglitazone and glimepiride) in the first-line and second-line treatment of type 2 diabetes patients.

Metformin, alone or in combination with other oral agents, has become the standard of care for the first-line treatment of type 2 diabetes patients. Similarly, metformin in combination with DPP4 inhibitors or GLP-1 analogs has become one of the most commonly prescribed treatment options for type 2 diabetes. In 2011, within the countries analyzed in this report (the US, EU5, Japan and BRIC countries), the US was the leading market with an estimated market share of 52.7%. Japan was the second leading market with an approximate market share of 12.8%, closely followed by Germany with an approximate market share of 7.5%. In 2011, Lantus was the leading drug, with approximate sales worth $3.6 billion and a market share of 18%. Januvia/Janumet, the DPP4 inhibitor was the second leading drug, with approximate sales of $3.4 billion and a market share of 17.1%. Actos was the third leading drug, with an approximate sales value of $1.9 billion and a market share of 9.6%.

Scope

The scope of the report includes -
  • An overview of type 2 diabetes which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
  • Annualized global type 2 diabetes therapeutics market revenue, annual cost of therapy and treatment usage patterns data by stage of the disease from 2002 to 2011, forecast for 9 years to 2020. 
  • Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France Japan and BRIC countries that include Brazil, Russia, India and China
  • Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events. 
  • Competitor assessment including drug launch analysis and drug sales forecasts.
  • Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, LCM activities, product positioning and drug sales forecast.
  • Analysis of unmet need in the market and target product profile including opportunity for target product. 
  • Technology trends analytic framework to assess strength of pipeline. 
  • Pipeline analysis data providing a split by stage of the disease and line of therapy across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include SGLT-2 inhibitors, 11
Table of Contents

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 9

2 Disease Overview 15
2.1 Overview 15
2.2 Epidemiology 15
2.3 Economic Impact of Diabetes 17
2.4 Etiology 17
2.5 Symptoms 18
2.6 Diagnosis 18
2.7 Pathology 20
2.8 Treatment 21
2.9 Treatment Guidelines 26
2.10 GlobalData In-Depth Report Guidance 27

3 Market Characterization 28
3.1 Global 28
3.2 The US 55
3.3 The UK 77
3.4 Germany 99
3.5 France 122
3.6 Italy 143
3.7 Spain 164
3.8 Japan 184
3.9 Brazil 204
3.10 India 219
3.11 China 234
3.12 Russia 248
3.13 Key Takeaway 263

4 Type 2 Diabetes Therapeutics - Opportunity and Unmet Need 264
4.1 Unmet Need 264
4.2 Opportunity for Target Products 266
4.3 Target Product Profile 267
4.4 Key Takeaway 268

5 Type 2 Diabetes Therapeutics - Competitive Assessment 269
5.1 Strategic Competitive Assessment 269
5.2 Launch Analysis and Sales Forecasts 273
5.3 Product Profiles 274
5.4 Recently Launched or Approved Products in the Market 372
5.5 Partners in Development - Marketed Products 387
5.6 Key Takeaway 387

6 Type 2 Diabetes Therapeutics - Pipeline Assessment 388
6.1 Overview 388
6.2 Pipeline Analysis by Phase of Development 388
6.3 Pipeline by Mechanism of Action 388
6.4 Strategic Pipeline Assessment 390
6.5 Trends in Type 2 Diabetes Pipeline 392
6.6 Type 2 Diabetes Pipeline - Regulatory Filing 395
6.7 Type 2 Diabetes Pipeline - Phase III 396
6.8 Type 2 Diabetes Pipeline - Phase II 397
6.9 Type 2 Diabetes Pipeline - Phase I 400
6.10 Type 2 Diabetes Pipeline - Preclinical and Discovery 403
6.11 Most Promising Drug Profiles 407
6.12 Partners in Development - Pipeline Products 437
6.13 Key Takeaway 444

7 Type 2 Diabetes Therapeutics - Clinical Trials Mapping 445
7.1 Clinical Trials 445
7.2 Patient Recruitment 452

8 Type 2 Diabetes Therapeutics - Implications for Future Market Competition 453
8.1 Key Events Impacting the Future Market 453
8.2 Market Impact Analysis 453
8.3 Future Market Scenario 454
8.4 Company Analysis 455

9 Type 2 Diabetes Therapeutics - Future Market Players 457
9.1 Introduction 457
9.2 Novo Nordisk 457
9.3 Amylin Pharmaceuticals 461
9.4 Takeda Pharmaceuticals 465
9.5 Boehringer Ingelheim 468
9.6 Eli Lilly and Company 471
9.7 GlaxoSmithKline 474
9.8 Novartis 477
9.9 Sanofi 480
9.10 F. Hoffmann La Roche 483
9.11 Bristol-Myers Squibb 485
9.12 Johnson & Johnson (J&J) 488
9.13 Astellas Pharma Inc. 495

10 Deals Analysis 502
10.1 Key Highlights 502
10.2 Key Deals Analysis 502
10.3 Deals Analysis by Geography 504
10.4 Deals Analysis by Deal Size 504

11 Type 2 Diabetes Therapeutics - Expert Opinion 505
11.1 Expert Opinion 505

12 Type 2 Diabetes Therapeutics - Appendix 507
12.1 Definitions 507
12.2 Acronyms 507
12.3 Research Methodology 509
12.4 Contact Us 513
12.5 Disclaimer 513
12.6 Bibliography 513

List of Table


Table 1: Type 2 Diabetes, Global, Prevalence Estimates for the 20-79 Age Group (million), 2000-2030 19
Table 2: Type 2 Diabetes, Top 10 Countries, Prevalence (million), 2010 and 2030 19
Table 3: Type 2 Diabetes, Top 10 Countries, Health Expenditures ($bn), 2011 20
Table 4: Type 2 Diabetes Therapeutics Market, Fasting Plasma Glucose Tests 21
Table 5: Type 2 Diabetes Therapeutics Market, Global, Sales Value ($bn), 2002-2011 31
Table 6: Type 2 Diabetes Therapeutics Market, Global, Sales Value ($bn) by Country, 2002-2011 33
Table 7: Type 2 Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2011 35
Table 8: Type 2 Diabetes Therapeutics Market, Global, Patient Volume (million), 2002-2011 37
Table 9: Type 2 Diabetes Therapeutics Market, Global, Treatment Usage Patterns (million), 2002-2011 39
Table 10: Type 2 Diabetes Therapeutics Market, Global, Sales Value ($bn), 2011-2020 44
Table 11: Type 2 Diabetes Therapeutics Market, Global, Sales Value ($bn) by Country, 2011-2020 45
Table 12: Type 2 Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2011-2020 47
Table 13: Type 2 Diabetes Therapeutics Market, Global, Patient Volume (million), 2011-2020 49
Table 14: Type 2 Diabetes Therapeutics Market, Global, Treatment Usage Patterns (million), 2011-2020 51
Table 15: Type 2 Diabetes Therapeutics Major Markets, Drug Sales ($m), 2002-2011 56
Table 16: Type 2 Diabetes Therapeutics Major Markets, Drug Sales ($m), 2012-2020 57
Table 17: Type 2 Diabetes Therapeutics Market, The US, Sales Value ($bn), 2002-2011 58
Table 18: Type 2 Diabetes Therapeutics Market, The US, Annual Cost of Therapy ($), 2002-2011 59
Table 19: Type 2 Diabetes Therapeutics Market, The US, Patient Volume (million), 2002-2011 61
Table 20: Type 2 Diabetes Therapeutics Market, The US, Treatment Usage Patterns (million), 2002-2011 63
Table 21: Type 2 Diabetes Therapeutics Market, The US, Sales Value ($bn), 2011-2020 68
Table 22: Type 2 Diabetes Therapeutics Market, The US, Annual Cost of Therapy ($), 2011-2020 69
Table 23: Type 2 Diabetes Therapeutics Market, The US, Patient Volume (million), 2011-2020 70
Table 24: Type 2 Diabetes Therapeutics Market, The US, Treatment Usage Patterns (million), 2011-2020 72
Table 25: Type 2 Diabetes Therapeutics Market, US, Drug Sales ($m), 2002-2011 77
Table 26: Type 2 Diabetes Therapeutics Market, US, Drug Sales ($m), 2012-2020 78
Table 27: Type 2 Diabetes Therapeutics Market, The UK, Sales Value ($m), 2002-2011 80
Table 28: Type 2 Diabetes Therapeutics Market, The UK, Annual Cost of Therapy ($), 2002-2011 81
Table 29: Type 2 Diabetes Therapeutics Market, The UK, Patient Volume (million), 2002-2011 83
Table 30: Type 2 Diabetes Therapeutics Market, The UK, Treatment Usage Patterns (million), 2002-2011 84
Table 31: Type 2 Diabetes Therapeutics Market, The UK, Sales Value ($m), 2011-2020 89
Table 32: Type 2 Diabetes Therapeutics Market, The UK, Annual Cost of Therapy ($), 2011-2020 90
Table 33: Type 2 Diabetes Therapeutics Market, The UK, Patient Volume (million), 2011-2020 92
Table 34: Type 2 Diabetes Therapeutics Market, The UK, Treatment Usage Patterns (million), 2011-2020 94
Table 35: Type 2 Diabetes Therapeutics Market, The UK, Drug Sales ($m), 2002-2011 99
Table 36: Type 2 Diabetes Therapeutics Market,The UK, Drug Sales ($m), 2012-2020 100
Table 37: Type 2 Diabetes Therapeutics Market, Germany, Sales Value ($m), 2002-2011 102
Table 38: Type 2 Diabetes Therapeutics Market, Germany, Annual Cost of Therapy ($), 2002-2011 103
Table 39: Type 2 Diabetes Therapeutics Market, Germany, Patient Volume (million), 2002-2011 105
Table 40: Type 2 Diabetes Therapeutics Market, Germany, Treatment Usage Patterns (million), 2002-2011 107
Table 41: Type 2 Diabetes Therapeutics Market, Germany, Sales Value ($m), 2011-2020 112
Table 42: Type 2 Diabetes Therapeutics Market, Germany, Annual Cost of Therapy ($), 2011-2020 113
Table 43: Type 2 Diabetes Therapeutics Market, Germany, Patient Volume (million), 2011-2020 115
Table 44: Type 2 Diabetes Therapeutics Market, Germany, Treatment Usage Patterns (million), 2011-2020 117
Table 45: Type 2 Diabetes Therapeutics Market, Germany, Drug Sales ($m), 2002-2011 122
Table 46: Type 2 Diabetes Therapeutics Market, Germany, Drug Sales ($m), 2012-2020 123
Table 47: Type 2 Diabetes Therapeutics Market, France, Sales Value ($m), 2002-2011 125
Table 48: Type 2 Diabetes Therapeutics Market, France, Annual Cost of Therapy ($), 2002-2011 126
Table 49: Type 2 Diabetes Therapeutics Market, France, Patient Volume (million), 2002-2011 128
Table 50: Type 2 Diabetes Therapeutics Market, France, Treatment Usage Patterns (million), 2002-2011 129
Table 51: Type 2 Diabetes Therapeutics Market, France, Sales Value ($m), 2011-2020 134
Table 52: Type 2 Diabetes Therapeutics Market, France, Annual Cost of Therapy ($), 2011-2020 135
Table 53: Type 2 Diabetes Therapeutics Market, France, Patient Volume (million), 2011-2020 136
Table 54: Type 2 Diabetes Therapeutics Market, France, Treatment Usage Patterns (million), 2011-2020 138
Table 55: Type 2 Diabetes Therapeutics Market, France, Drug Sales ($m), 2002-2011 143
Table 56: Type 2 Diabetes Therapeutics Market, France, Drug Sales ($m), 2012-2020 144
Table 57: Type 2 Diabetes Therapeutics Market, Italy, Sales Value ($m), 2002-2011 146
Table 58: Type 2 Diabetes Therapeutics Market, Italy, Annual Cost of Therapy ($), 2002-2011 147
Table 59: Type 2 Diabetes Therapeutics Market, Italy, Patient Volume (million), 2002-2011 148
Table 60: Type 2 Diabetes Therapeutics Market, Italy, Treatment Usage Patterns (million), 2002-2011 150
Table 61: Type 2 Diabetes Therapeutics Market, Italy, Sales Value ($m), 2011-2020 155
Table 62: Type 2 Diabetes Therapeutics Market, Italy, Annual Cost of Therapy ($), 2011-2020 156
Table 63: Type 2 Diabetes Therapeutics Market, Italy, Patient Volume (million), 2011-2020 157
Table 64: Type 2 Diabetes Therapeutics Market, Italy, Treatment Usage Patterns (million), 2011-2020 159
Table 65: Type 2 Diabetes Therapeutics Market, Italy, Drug Sales ($m), 2002-2011 164
Table 66: Type 2 Diabetes Therapeutics Market, Italy, Drug Sales ($m), 2012-2020 165
Table 67: Type 2 Diabetes Therapeutics Market, Spain, Sales Value ($m), 2002-2011 167
Table 68: Type 2 Diabetes Therapeutics Market, Spain, Annual Cost of Therapy ($), 2002-2011 168
Table 69: Type 2 Diabetes Therapeutics Market, Spain, Patient Volume (million), 2002-2011 169
Table 70: Type 2 Diabetes Therapeutics Market, Spain, Treatment Usage Patterns (million), 2002-2011 170
Table 71: Type 2 Diabetes Therapeutics Market, Spain, Sales Value ($m), 2011-2020 175
Table 72: Type 2 Diabetes Therapeutics Market, Spain, Annual Cost of Therapy ($), 2011-2020 176
Table 73: Type 2 Diabetes Therapeutics Market, Spain, Patient Volume (million), 2011-2020 177
Table 74: Type 2 Diabetes Therapeutics Market, Spain, Treatment Usage Patterns (million), 2011-2020 179
Table 75: Type 2 Diabetes Therapeutics Market, Spain, Drug Sales ($m), 2002-2011 184
Table 76: Type 2 Diabetes Therapeutics Market, Spain, Drug Sales ($m), 2012-2020 185
Table 77: Type 2 Diabetes Therapeutics Market, Japan, Sales Value ($m), 2002-2011 187
Table 78: Type 2 Diabetes Therapeutics Market, Japan, Annual Cost of Therapy ($), 2002-2011 188
Table 79: Type 2 Diabetes Therapeutics Market, Japan, Patient Volume (million), 2002-2011 189
Table 80: Type 2 Diabetes Therapeutics Market, Japan, Treatment Usage Patterns (million), 2002-2011 190
Table 81: Type 2 Diabetes Therapeutics Market, Japan, Sales Value ($m), 2011-2020 195
Table 82: Type 2 Diabetes Therapeutics Market, Japan, Annual Cost of Therapy ($), 2011-2020 196
Table 83: Type 2 Diabetes Therapeutics Market, Japan, Patient Volume (million), 2011-2020 197
Table 84: Type 2 Diabetes Therapeutics Market, Japan, Treatment Usage Patterns (million), 2011-2020 199
Table 85: Type 2 Diabetes Therapeutics Market, Japan, Drug Sales ($m), 2002-2011 204
Table 86: Type 2 Diabetes Therapeutics Market, Japan, Drug Sales ($m), 2012-2020 205
Table 87: Type 2 Diabetes Therapeutics Market, Brazil, Sales Value ($m), 2002-2011 207
Table 88: Type 2 Diabetes Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2002-2011 208
Table 89: Type 2 Diabetes Therapeutics Market, Brazil, Patient Volume (million), 2002-2011 209
Table 90: Type 2 Diabetes Therapeutics Market, Brazil, Treatment Usage Patterns (million), 2002-2011 210
Table 91: Type 2 Diabetes Therapeutics Market, Brazil, Sales Value ($m), 2011-2020 215
Table 92: Type 2 Diabetes Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2011-2020 216
Table 93: Type 2 Diabetes Therapeutics Market, Brazil, Patient Volume, (million) 2011-2020 217
Table 94: Type 2 Diabetes Therapeutics Market, Brazil, Treatment Usage Patterns (million), 2011-2020 219
Table 95: Type 2 Diabetes Therapeutics Market, India, Sales Value ($m), 2002-2011 222
Table 96: Type 2 Diabetes Therapeutics Market, India, Annual Cost of Therapy ($), 2002-2011 223
Table 97: Type 2 Diabetes Therapeutics Market, India, Patient Volume (million), 2002-2011 224
Table 98: Type 2 Diabetes Therapeutics Market, India, Treatment Usage Patterns (million), 2002-2011 225
Table 99: Type 2 Diabetes Therapeutics Market, India, Sales Value ($m), 2011-2020 230
Table 100: Type 2 Diabetes Therapeutics Market, India, Annual Cost of Therapy ($), 2011-2020 231
Table 101: Type 2 Diabetes Therapeutics Market, India, Patient Volume (million), 2011-2020 232
Table 102: Type 2 Diabetes Therapeutics Market, India, Treatment Usage Patterns (million), 2011-2020 234
Table 103: Type 2 Diabetes Therapeutics Market, China, Sales Value ($m), 2002-2011 237
Table 104: Type 2 Diabetes Therapeutics Market, China, Annual Cost of Therapy ($), 2002-2011 238
Table 105: Type 2 Diabetes Therapeutics Market, China, Patient Volume (million) 2002-2011 239
Table 106: Type 2 Diabetes Therapeutics Market, China, Treatment Usage Patterns (million), 2002-2011 240
Table 107: Type 2 Diabetes Therapeutics Market, China, Sales Value ($m), 2011-2020 245
Table 108: Type 2 Diabetes Therapeutics Market, China, Annual Cost of Therapy ($), 2011-2020 246
Table 109: Type 2 Diabetes Therapeutics Market, China, Patient Volume (million), 2011-2020 247
Table 110: Type 2 Diabetes Therapeutics Market, China, Treatment Usage Patterns (million), 2011-2020 249
Table 111: Type 2 Diabetes Therapeutics Market, Russia, Sales Value ($m), 2002-2011 252
Table 112: Type 2 Diabetes Therapeutics Market, Russia, Annual Cost of Therapy ($), 2002-2011 253
Table 113: Type 2 Diabetes Therapeutics Market, Russia, Patient Volume (million), 2002-2011 254
Table 114: Type 2 Diabetes Therapeutics Market, Russia, Treatment Usage Patterns (million), 2002-2011 255
Table 115: Type 2 Diabetes Therapeutics Market, Russia, Sales Value ($m), 2011-2020 260
Table 116: Type 2 Diabetes Therapeutics Market, Russia, Annual Cost of Therapy ($), 2011-2020 261
Table 117: Type 2 Diabetes Therapeutics Market, Russia, Patient Volume (million), 2011-2020 262
Table 118: Type 2 Diabetes Therapeutics Market, Russia, Treatment Usage Patterns (million), 2011-2020 264
Table 119: Type 2 Diabetes Therapeutics Market, Global, Characteristics of Ideal Drug that Would Satisfy the Unmet Needs, 2011 270
Table 120: Type 2 Diabetes Therapeutics Market, Global, Description of Ideal Drug that Would Satisfy the Unmet Needs, 2011 270
Table 121: Type 2 Diabetes Therapeutics Market, Global, Benchmarking Major Marketed Products, 2011 277
Table 122: Type 2 Diabetes, Global, Actos, Adverse Effects Incidence, 2011 281
Table 123: Type 2 Diabetes Therapeutics Market, Global, Avandia, Cardiovascular Adverse Effects Incidence, 2011 285
Table 124: Type 2 Diabetes Therapeutics Market, Global, Metformin, Adverse Effects Incidence, 2011 289
Table 125: Type 2 Diabetes Therapeutics Market, Global, Amaryl, Adverse Effects Incidence, 2011 293
Table 126: Type 2 Diabetes Therapeutics Market, Global, Amaryl, Regulatory Approval, 2011 294
Table 127: Type 2 Diabetes Therapeutics Market, Global, Glyburide, Clinical Study Details, 2011 298
Table 128: Type 2 Diabetes Therapeutics Market, Global, Glyburide, Clinical Study Details, 2011 298
Table 129: Type 2 Diabetes Therapeutics Market, Global, Glipizide, Clinical Study Details, 2011 302
Table 130: Type 2 Diabetes Therapeutics Market, Global, Precose, Clinical Study Details, 2011 305
Table 131: Type 2 Diabetes Therapeutics Market, Global, Glyset, Clinical Study Details, 2011 309
Table 132: Type 2 Diabetes Therapeutics Market, Global, Glyset, Regulatory Approval, 2011 310
Table 133: Type 2 Diabetes Therapeutics Market, Global, Basen, Regulatory Approval, 2011 313
Table 134: Type 2 Diabetes Therapeutics Market, Global, Januvia, Adverse Effects Incidence, 2011 316
Table 135: Type 2 Diabetes Therapeutics Market, Global, Januvia, Clinical Study Details as Monotherapy, 2011 317
Table 136: Type 2 Diabetes Therapeutics Market, Global, Januvia, Clinical Study Details as Add-on to Metformin and Rosiglitazone, 2011 318
Table 137: Type 2 Diabetes Therapeutics Market, Global, Januvia, Clinical Study Details as Add-on to Metformin, 2011 319
Table 138: Type 2 Diabetes Therapeutics Market, Global, Januvia, Clinical Study Details as Add-on to Pioglitaozone, 2011 320
Table 139: Type 2 Diabetes Therapeutics Market, Global, Januvia, Regulatory Approval, 2011 321
Table 140: Type 2 Diabetes Therapeutics Market, Global, Onglyza, Adverse Effects Incidence, 2011 325
Table 141: Type 2 Diabetes Therapeutics Market, Global, Galvus, Efficacy Monotherapy Trial, 2011 330
Table 142: Type 2 Diabetes Therapeutics Market, Global, Galvus, Efficacy Combination Trial, 2011 331
Table 143: Type 2 Diabetes Therapeutics Market, Global, Byetta, Efficacy, 2011 339
Table 144: Type 2 Diabetes Therapeutics Market, Global, Byetta, Adverse Effects Incidence, 2011 340
Table 145: Type 2 Diabetes Therapeutics Market, Global, Victoza, Adverse Effects Incidence, 2011 345
Table 146: Type 2 Diabetes Therapeutics Market, Global, Humalog, Clinical Study Details as a Monotherapy, 2011 357
Table 147: Type 2 Diabetes Therapeutics Market, Global, Humalog, Comparative Clinical Study Details in Combination with a Sulfonylurea, 2011 358
Table 148: Type 2 Diabetes Therapeutics Market, Global, Humulin, Regulatory Approval, 2011 361
Table 149: Type 2 Diabetes Therapeutics Market, Global, Novolog, Clinical Study Details, 2011 365
Table 150: Type 2 Diabetes Therapeutics Market, Global, Novolog, Clinical Study Details as a Pump Therapy, 2011 365
Table 151: Type 2 diabetes Therapeutics Market, Global, Novolog, Regulatory Approvals, 2011 366
Table 152: Type 2 Diabetes Therapeutics Market, Global, Apidra, Adverse Effects Incidence, 2011 368
Table 153: Type 2 Diabetes Therapeutics Market, Global, Apidra, Clinical Study Details, 2011 369
Table 154: Type 2 Diabetes Therapeutics Market, Global, Apidra, Regulatory Approvals, 2011 369
Table 155: Type 2 diabetes Therapeutics Market, Global, Welchol, Clinical Study Details, 2011 372
Table 156: Type 2 Diabetes Therapeutics Market, Global, Welchol, Regulatory Approvals, 2011 373
Table 157: Type 2 Diabetes Therapeutics Market, Global, Cycloset, Clinical Study Details, 2011 379
Table 158: Type 2 Diabetes Therapeutics Market, Global, Bydureon, (DURATION-2) Trial Efficacy, 2011 387
Table 159: Type 2 Diabetes Therapeutics Market, Global, Desirable Drug Delivery Methods for Diabetes are Currently Unavailable, 2011 396
Table 160: Type 2 Diabetes Therapeutics Market, Regulatory Filing, October 2011 398
Table 161: Type 2 Diabetes Therapeutics Market, Global, Phase III Pipeline, October 2011 399
Table 162: Type 2 Diabetes Therapeutics Market, Global, Phase II Pipeline, October 2011 400
Table 163: Type 2 Diabetes Therapeutics Market, Global, Phase I Pipeline, October 2011 403
Table 164: Type 2 Diabetes Therapeutics Market, Global, Preclinical and Discovery Pipeline, October, 2011 406
Table 165: Type 2 Diabetes Therapeutics Market, Global, Co-Development Agreements, 2010–2011 443
Table 166: Type 2 Diabetes Therapeutics Market, Global, Licensing Agreements, 2010–2011 447
Table 167: Type 2 Diabetes Therapeutics Market, Global, Clinical Trials by Status, October 2011 448
Table 168: Type 2 Diabetes Therapeutics Market, Global, Clinical Trials by Country, October 2011 450
Table 169: Type 2 Diabetes Therapeutics Market, Global, Clinical Trials by Phase, October 2011 451
Table 170: Type 2 Diabetes Therapeutics Market, Global, Clinical Trials by Sponsor Type, October 2011 452
Table 171: Type 2 Diabetes Therapeutics Market, Global, Clinical Trials, Leading Sponsors, October 2011 453
Table 172: Type 2 Diabetes Therapeutics Market, Global, Clinical Trials, Leading Company Sponsors, October 2011 454
Table 173: Type 2 Diabetes Therapeutics Market, Global, Clinical Trials, Average Number of Patients Recruited, October 2011 455
Table 174: Type 2 Diabetes Therapeutics Market, Global, Merger and Acquisition Deals by Geography, 2008-2011 505
Table 175:Type 2 Diabetes Therapeutics Market, Global, Merger and Acquisition Deals by Geography, 2011 507
Table 176:Type 2 Diabetes Therapeutics Market, Global, Merger and Acquisition Deals by Deal Size, 2011 507

List of Chart


Figure 1: Type 2 Diabetes, Global, Treatment Guidelines, 2011 28
Figure 2: Type 2 Diabetes Therapeutics Market, Global, Sales Value ($bn), 2002-2011 30
Figure 3: Type 2 Diabetes Therapeutics Market, Global, Sales Value ($bn) by Country, 2002-2011 32
Figure 4: Type 2 Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2011 34
Figure 5: Type 2 Diabetes Therapeutics Market, Global, Patient Volume (million), 2002-2011 36
Figure 6:    Type 2 Diabetes Therapeutics Market, Global, Treatment Usage Patterns (million), 2002-2011 38
Figure 7: Type 2 Diabetes Therapeutics Market, Global, Market Drivers and Restraints, 2011 40
Figure 8: Type 2 Diabetes Therapeutics Market, Global, The Impact of Historical Events on the Market, 2011 42
Figure 9: Type 2 Diabetes Therapeutics Market, Global, Sales Value ($bn), 2011-2020 43
Figure 10: Type 2 Diabetes Therapeutics Market, Global, Sales Value ($bn) by Country, 2011-2020 44
Figure 11: Type 2 Diabetes Therapeutics Market, Global, Annual Cost of Therapy ($), 2011-2020 46
Figure 12: Type 2 Diabetes Therapeutics Market, Global, Patient Volume (million), 2011-2020 48
Figure 13: Type 2 Diabetes Therapeutics Market, Global, Treatment Usage Patterns (million), 2011-2020 50
Figure 14: Type 2 Diabetes Therapeutics Market, Global, Future Market Drivers and Restraints, 2011-2020 52
Figure 15: Type 2 Diabetes Therapeutics Major Markets, Drug Sales ($bn), 2002-2020 53
Figure 16: Type 2 Diabetes Therapeutics Market, The US, Sales Value ($bn), 2002-2011 57
Figure 17: Type 2 Diabetes Therapeutics Market, The US, Annual Cost of Therapy ($), 2002-2011 58
Figure 18: Type 2 Diabetes Therapeutics Market, The US, Patient Volume (million), 2002-2011 60
Figure 19: Type 2 Diabetes Therapeutics Market, The US, Treatment Usage Patterns (million), 2002-2011 62
Figure 20: Type 2 Diabetes Therapeutics Market, The US, Market Drivers and Restraints, 2011 64
Figure 21: Type 2 Diabetes Therapeutics Market, The US, The Impact of Historical Events on the Market, 2011 66
Figure 22: Type 2 Diabetes Therapeutics Market, The US, Sales Value ($bn), 2011-2020 67
Figure 23: Type 2 Diabetes Therapeutics Market, The US, Annual Cost of Therapy ($), 2011-2020 68
Figure 24: Type 2 Diabetes Therapeutics Market, The US, Patient Volume (million), 2011-2020 69
Figure 25: Type 2 Diabetes Therapeutics Market, The US, Treatment Usage Patterns (million), 2011-2020 71
Figure 26: Type 2 Diabetes Therapeutics Market, The US, Future Market Drivers and Restraints, 2011-2020 73
Figure 27: Type 2 Diabetes Therapeutics Market, The US, Drug Sales ($bn), 2002-2020 74
Figure 28: Type 2 Diabetes Therapeutics Market, The UK, Sales Value ($m), 2002-2011 79
Figure 29: Type 2 Diabetes Therapeutics Market, The UK, Annual Cost of Therapy ($), 2002-2011 80
Figure 30: Type 2 Diabetes Therapeutics Market, The UK, Patient Volume (million), 2002-2011 82
Figure 31: Type 2 Diabetes Therapeutics Market, The UK, Treatment Usage Patterns (million), 2002-2011 83
Figure 32: Type 2 Diabetes Therapeutics Market, The UK, Market Drivers and Restraints, 2011 85
Figure 33: Type 2 Diabetes Therapeutics Market, The UK, The Impact of Historical Events on the Market, 2011 87
Figure 34: Type 2 Diabetes Therapeutics Market, The UK, Sales Value ($m), 2011-2020 88
Figure 35: Type 2 Diabetes Therapeutics Market, The UK, Annual Cost of Therapy ($), 2011-2020 89
Figure 36: Type 2 Diabetes Therapeutics Market, The UK, Patient Volume (million), 2011-2020 91
Figure 37: Type 2 Diabetes Therapeutics Market, The UK, Treatment Usage Patterns (million), 2011-2020 93
Figure 38: Type 2 Diabetes Therapeutics Market, The UK, Future Market Drivers and Restraints, 2011-2020 95
Figure 39: Type 2 Diabetes Therapeutics Market, The UK, Drug Sales ($m), 2002-2020 96
Figure 40: Type 2 Diabetes Therapeutics Market, Germany, Sales Value ($m), 2002-2011 101
Figure 41: Type 2 Diabetes Therapeutics Market, Germany, Annual Cost of Therapy ($), 2002-2011 102
Figure 42: Type 2 Diabetes Therapeutics Market, Germany, Patient Volume (million), 2002-2011 104
Figure 43: Type 2 Diabetes Therapeutics Market, Germany, Treatment Usage Patterns (million), 2002-2011 106
Figure 44: Type 2 Diabetes Therapeutics Market, Germany, Market Drivers and Restraints, 2011 108
Figure 45: Type 2 Diabetes Therapeutics Market, Germany, The Impact of Historical Events on the Market, 2011 110
Figure 46: Type 2 Diabetes Therapeutics Market, Germany, Sales Value ($m), 2011-2020 111
Figure 47: Type 2 Diabetes Therapeutics Market, Germany, Annual Cost of Therapy ($), 2011-2020 112
Figure 48: Type 2 Diabetes Therapeutics Market, Germany, Patient Volume (million), 2011-2020 114
Figure 49: Type 2 Diabetes Therapeutics Market, Germany, Treatment Usage Patterns (million), 2011-2020 116
Figure 50: Type 2 Diabetes Therapeutics Market, Germany, Future Market Drivers and Restraints, 2011-2020 118
Figure 51: Type 2 Diabetes Therapeutics Market, Germany, Drug Sales ($m), 2002-2020 119
Figure 52: Type 2 Diabetes Therapeutics Market, France, Sales Value ($m), 2002-2011 124
Figure 53: Type 2 Diabetes Therapeutics Market, France, Annual Cost of Therapy ($), 2002-2011 125
Figure 54: Type 2 Diabetes Therapeutics Market, France, Patient Volume (million), 2002-2011 127
Figure 55: Type 2 Diabetes Therapeutics Market, France, Treatment Usage Patterns (million), 2002-2011 128
Figure 56: Type 2 Diabetes Therapeutics Market, France, Market Drivers and Restraints, 2011 130
Figure 57: Type 2 Diabetes Therapeutics Market, France, The Impact of Historical Events on the Market, 2011 132
Figure 58: Type 2 Diabetes Therapeutics Market, France, Sales Value ($m), 2011-2020 133
Figure 59: Type 2 Diabetes Therapeutics Market, France, Annual Cost of Therapy ($), 2011-2020 134
Figure 60: Type 2 Diabetes Therapeutics Market, France, Patient Volume (million), 2011-2020 135
Figure 61: Type 2 Diabetes Therapeutics Market, France, Treatment Usage Patterns (million), 2011-2020 137
Figure 62: Type 2 Diabetes Therapeutics Market, France, Future Market Drivers and Restraints, 2011-2020 139
Figure 63: Type 2 Diabetes Therapeutics Market, France, Drug Sales ($m), 2002-2020 140
Figure 64: Type 2 Diabetes Therapeutics Market, Italy, Sales Value ($m), 2002-2011 145
Figure 65: Type 2 Diabetes Therapeutics Market, Italy, Annual Cost of Therapy ($), 2002-2011 146
Figure 66: Type 2 Diabetes Therapeutics Market, Italy, Patient Volume (million), 2002-2011 147
Figure 67: Type 2 Diabetes Therapeutics Market, Italy, Treatment Usage Patterns (million), 2002-2011 149
Figure 68: Type 2 Diabetes Therapeutics Market, Italy, Market Drivers and Restraints, 2011 151
Figure 69: Type 2 Diabetes Therapeutics Market, Italy, The Impact of Historical Events on the Market, 2011 153
Figure 70: Type 2 Diabetes Therapeutics Market, Italy, Sales Value ($m), 2011-2020 154
Figure 71: Type 2 Diabetes Therapeutics Market, Italy, Annual Cost of Therapy ($), 2011-2020 155
Figure 72: Type 2 Diabetes Therapeutics Market, Italy, Patient Volume (million), 2011-2020 156
Figure 73: Type 2 Diabetes Therapeutics Market, Italy, Treatment Usage Patterns (million), 2011-2020 158
Figure 74: Type 2 Diabetes Therapeutics Market, Italy, Future Market Drivers and Restraints, 2011-2020 160
Figure 75: Type 2 Diabetes Therapeutics Market, Italy, Drug Sales ($m), 2002-2020 161
Figure 76: Type 2 Diabetes Therapeutics Market, Spain, Sales Value ($m), 2002-2011 166
Figure 77: Type 2 Diabetes Therapeutics Market, Spain, Annual Cost of Therapy ($), 2002-2011 167
Figure 78: Type 2 Diabetes Therapeutics Market, Spain, Patient Volume (million), 2002-2011 168
Figure 79: Type 2 Diabetes Therapeutics Market, Spain, Treatment Usage Patterns (million), 2002-2011 169
Figure 80: Type 2 Diabetes Therapeutics Market, Spain, Market Drivers and Restraints, 2011 171
Figure 81: Type 2 Diabetes Therapeutics Market, Spain, The Impact of Historical Events on the Market, 2011 173
Figure 82: Type 2 Diabetes Therapeutics Market, Spain, Sales Value ($m), 2011-2020 174
Figure 83: Type 2 Diabetes Therapeutics Market, Spain, Annual Cost of Therapy ($), 2011-2020 175
Figure 84: Type 2 Diabetes Therapeutics Market, Spain, Patient Volume (million), 2011-2020 176
Figure 85: Type 2 Diabetes Therapeutics Market, Spain, Treatment Usage Patterns (million), 2011-2020 178
Figure 86: Type 2 Diabetes Therapeutics Market, Spain, Future Market Drivers and Restraints, 2011-2020 180
Figure 87: Type 2 Diabetes Therapeutics Market, Spain, Drug Sales ($m), 2002-2020 181
Figure 88: Type 2 Diabetes Therapeutics Market, Japan, Sales Value ($m), 2002-2011 186
Figure 89: Type 2 Diabetes Therapeutics Market, Japan, Annual Cost of Therapy ($), 2002-2011 187
Figure 90: Type 2 Diabetes Therapeutics Market, Japan, Patient Volume (million), 2002-2011 188
Figure 91: Type 2 Diabetes Therapeutics Market, Japan, Treatment Usage Patterns (million), 2002-2011 189
Figure 92: Type 2 Diabetes Therapeutics Market, Japan, Market Drivers and Restraints, 2011 191
Figure 93: Type 2 Diabetes Therapeutics Market, Japan, The Impact of Historical Events on the Market, 2011 193
Figure 94: Type 2 Diabetes Therapeutics Market, Japan, Sales Value ($m), 2011-2020 194
Figure 95: Type 2 Diabetes Therapeutics Market, Japan, Annual Cost of Therapy ($), 2011-2020 195
Figure 96: Type 2 Diabetes Therapeutics Market, Japan, Patient Volume (million), 2011-2020 196
Figure 97: Type 2 Diabetes Therapeutics Market, Japan, Treatment Usage Patterns (million), 2011-2020 198
Figure 98: Type 2 Diabetes Therapeutics Market, Japan, Future Market Drivers and Restraints, 2011-2020 200
Figure 99: Type 2 Diabetes Therapeutics Market, Japan, Drug Sales ($m), 2002-2020 201
Figure 100: Type 2 Diabetes Therapeutics Market, Brazil, Sales Value ($m), 2002-2011 206
Figure 101: Type 2 Diabetes Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2002-2011 207
Figure 102: Type 2 Diabetes Therapeutics Market, Brazil, Patient Volume (million), 2002-2011 208
Figure 103: Type 2 Diabetes Therapeutics Market, Brazil, Treatment Usage Patterns (million), 2002-2011 209
Figure 104: Type 2 Diabetes Therapeutics Market, Brazil, Market Drivers and Restraints, 2011 211
Figure 105: Type 2 Diabetes Therapeutics Market, Brazil, The Impact of Historical Events on the Market, 2011 213
Figure 106: Type 2 Diabetes Therapeutics Market, Brazil, Sales Value ($m), 2011-2020 214
Figure 107: Type 2 Diabetes Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2011-2020 215
Figure 108: Type 2 Diabetes Therapeutics Market, Brazil, Patient Volume (million), 2011-2020 216
Figure 109: Type 2 Diabetes Therapeutics Market, Brazil, Treatment Usage Patterns (million), 2011-2020 218
Figure 110: Type 2 Diabetes Therapeutics Market, Brazil, Future Market Drivers and Restraints, 2011-2020 220
Figure 111: Type 2 Diabetes Therapeutics Market, India, Sales Value ($m), 2002-2011 221
Figure 112: Type 2 Diabetes Therapeutics Market, India, Annual Cost of Therapy ($), 2002-2011 222
Figure 113: Type 2 Diabetes Therapeutics Market, India, Patient Volume (million), 2002-2011 223
Figure 114: Type 2 Diabetes Therapeutics Market, India, Treatment Usage Patterns (million), 2002-2011 224
Figure 115: Type 2 Diabetes Therapeutics Market, India, Market Drivers and Restraints, 2011 226
Figure 116: Type 2 Diabetes Therapeutics Market, India, The Impact of Historical Events on the Market, 2011 228
Figure 117: Type 2 Diabetes Therapeutics Market, India, Sales Value ($m), 2011-2020 229
Figure 118: Type 2 Diabetes Therapeutics Market, India, Annual Cost of Therapy ($), 2011-2020 230
Figure 119: Type 2 Diabetes Therapeutics Market, India, Patient Volume (million), 2011-2020 231
Figure 120: Type 2 Diabetes Therapeutics Market, India, Treatment Usage Patterns (million), 2011-2020 233
Figure 121: Type 2 Diabetes Therapeutics Market, India, Future Market Drivers and Restraints, 2011-2020 235
Figure 122: Type 2 Diabetes Therapeutics Market, China, Sales Value ($m), 2002-2011 236
Figure 123: Type 2 Diabetes Therapeutics Market, China, Annual Cost of Therapy ($), 2002-2011 237
Figure 124: Type 2 Diabetes Therapeutics Market, China, Patient Volume (million), 2002-2011 238
Figure 125: Type 2 Diabetes Therapeutics Market, China, Treatment Usage Patterns (million), 2002-2011 239
Figure 126: Type 2 Diabetes Therapeutics Market, China, Market Drivers and Restraints, 2011 241
Figure 127: Type 2 Diabetes Therapeutics Market, China, The Impact of Historical Events on the Market, 2011 243
Figure 128: Type 2 Diabetes Therapeutics Market, China, Sales Value ($m), 2011-2020 244
Figure 129: Type 2 Diabetes Therapeutics Market, China, Annual Cost of Therapy ($), 2011-2020 245
Figure 130: Type 2 Diabetes Therapeutics Market, China, Patient Volume (million), 2011-2020 246
Figure 131: Type 2 Diabetes Therapeutics Market, China, Treatment Usage Patterns (million), 2011-2020 248
Figure 132: Type 2 Diabetes Therapeutics Market, China, Future Market Drivers and Restraints, 2011-2020 250
Figure 133: Type 2 Diabetes Therapeutics Market, Russia, Sales Value ($m), 2002-2011 250
Figure 134: Type 2 Diabetes Therapeutics Market, Russia, Annual Cost of Therapy ($), 2002-2011 251
Figure 135: Type 2 Diabetes Therapeutics Market, Russia, Patient Volume (million), 2002-2011 253
Figure 136: Type 2 Diabetes Therapeutics Market, Russia, Treatment Usage Patterns (million), 2002-2011 254
Figure 137: Type 2 Diabetes Therapeutics Market, Russia, Market Drivers and Restraints, 2011 256
Figure 138: Type 2 Diabetes Therapeutics Market, Russia, The Impact of Historical Events on the Market, 2011 258
Figure 139: Type 2 Diabetes Therapeutics Market, Russia, Sales Value ($m), 2011-2020 259
Figure 140: Type 2 Diabetes Therapeutics Market, Russia, Annual Cost of Therapy ($), 2011-2020 260
Figure 141: Type 2 Diabetes Therapeutics Market, Russia, Patient Volume (million), 2011-2020 261
Figure 142: Type 2 Diabetes Therapeutics Market, Russia, Treatment Usage Patterns (million), 2011-2020 263
Figure 143: Type 2 Diabetes Therapeutics Market, Russia, Future Market Drivers and Restraints, 2011-2020 265
Figure 144: Type 2 Diabetes Therapeutics Market, Global, Opportunity and Unmet Need, 2011 268
Figure 145: Type 2 Diabetes Therapeutics Market, Global, Strategic Competitor Assessment of Major Marketed Drugs, 2011 274
Figure 146: Type 2 Diabetes Therapeutics Market, Global, Sales Forecast Split by Drugs, 2002-2020 275
Figure 147: Type 2 Diabetes Therapeutics Market, Global, Actos, Life Cycle Management Activities 281
Figure 148: Type 2 Diabetes Therapeutics Market, Global, Actos Sales Forecast ($m), 2002–2020 282
Figure 149: Type 2 Diabetes Therapeutics Market, Global, Actos, Market Share Analysis (%), 2011 283
Figure 150: Type 2 Diabetes Therapeutics Market, Global, Avandia, Sales Forecast ($m), 2002–2020 286
Figure 151: Type 2 Diabetes Therapeutics Market, Global, Metformin, Sales Forecast ($m), 2002–2020 289
Figure 152: Type 2 Diabetes Therapeutics Market, Global, Metformin, Market Share Analysis (%), 2011 290
Figure 153: Type 2 Diabetes Therapeutics Market, Global, Amaryl, Sales Forecast ($m), 2002–2020 294
Figure 154: Type 2 Diabetes Therapeutics Market, Global, Amaryl, Market Share Analysis (%), 2011 295
Figure 155: Type 2 Diabetes Therapeutics Market, Global, Glyburide Product sales Forecast ($m), 2002–2020 299
Figure 156: Type 2 Diabetes Therapeutics Market, Global, Glyburide Products, Market Share Analysis (%), 2011 300
Figure 157: Type 2 Diabetes Therapeutics Market, Global, Glipizide Sales Forecast ($m), 2002–2020 302
Figure 158: Type 2 Diabetes Therapeutics Market, Global, Glipizide, Market Share Analysis (%), 2011 303
Figure 159: Type 2 Diabetes Therapeutics Market, Global, Precose/Glucobay Sales Forecast ($m), 2002-2020 305
Figure 160: Type 2 Diabetes Therapeutics Market, Global, Precose/Glucobay, Market Share Analysis (%), 2011 306
Figure 161: Type 2 Diabetes Therapeutics Market, Global, Glyset Sales Forecast ($m), 2002–2020 310
Figure 162: Type 2 Diabetes Therapeutics Market, Global, Glyset, Market Share Analysis (%), 2011 311
Figure 163: Type 2 Diabetes Therapeutics Market, Global, Basen, Sales Forecast ($m), 2002–2020 313
Figure 164: Type 2 Diabetes Therapeutics Market, Global, Januvia, Mechanism of Action, 2011 314
Figure 165: Type 2 Diabetes Therapeutics Market, Global, Januvia, Chemical Structure, 2011 314
Figure 166: Type 2 Diabetes Therapeutics Market, Global, Januvia, Life Cycle Management Activities 320
Figure 167: Type 2 Diabetes Therapeutics Market, Global, Januvia Product sales Forecast ($m), 2006-2020 321
Figure 168: Type 2 Diabetes Therapeutics Market, Global, Januvia, Market Share Analysis (%), 2011 322
Figure 169: Type 2 Diabetes Therapeutics Market, Global, Onglyza, Chemical Structure, 2011 323
Figure 170: Type 2 Diabetes Therapeutics Market, Global, Onglyza, Life Cycle Management Activities 325
Figure 171: Type 2 Diabetes Therapeutics Market, Global, Onglyza Product sales Forecast ($m), 2009–2020 326
Figure 172: Type 2 Diabetes Therapeutics Market, Global, Onglyza, Market Share Analysis (%), 2011 327
Figure 173: Type 2 Diabetes Therapeutics Market, Global, Galvus, Chemical Structure, 2011 328
Figure 174: Type 2 Diabetes Therapeutics Market, Global, Galvus, Life Cycle Management Activities 331
Figure 175: Type 2 Diabetes Therapeutics Market, Global, Galvus Sales Forecast ($m), 2007–2020 332
Figure 176: Type 2 Diabetes Therapeutics Market, Global, Galvus, Market Share Analysis (%), 2011 333
Figure 177: Type 2 Diabetes Therapeutics Market, Global, Starlix Sales Forecast ($m), 2002–2020 335
Figure 178: Type 2 Diabetes Therapeutics Market, Global, Starlix, Market Share Analysis (%), 2011 336
Figure 179: Type 2 Diabetes Therapeutics Market, Global, Byetta, Chemical Structure, 2011 337
Figure 180: Type 2 Diabetes Therapeutics Market, Global, Byetta, Life Cycle Management Activities 340
Figure 181: Type 2 Diabetes Therapeutics Market, Global, Byetta Sales Forecast ($m), 2005–2020 341
Figure 182: Type 2 Diabetes Therapeutics Market, Global, Byetta, Market Share Analysis (%), 2011 342
Figure 183: Type 2 Diabetes Therapeutics Market, Global, Victoza, Chemical Structure, 2011 343
Figure 184: Type 2 Diabetes Therapeutics Market, Global, Victoza, Life Cycle Management Activities 346
Figure 185: Type 2 Diabetes Therapeutics Market, Global, Victoza Sales Forecast ($m), 2009–2020 347
Figure 186: Type 2 Diabetes Therapeutics Market, Global, Victoza, Market Share Analysis (%), 2011 348
Figure 187: Type 2 Diabetes Therapeutics Market, Global, Lantus, Chemical Structure, 2011 349
Figure 188: Type 2 Diabetes Therapeutics Market, Global, Lantus, Life Cycle Management Activities 350
Figure 189: Type 2 Diabetes Therapeutics Market, Global, Lantus Sales Forecast ($m), 2002–2020 351
Figure 190: Type 2 Diabetes Therapeutics Market, Global, Lantus, Market Share Analysis (%), 2011 351
Figure 191: Type 2 Diabetes Therapeutics Market, Global, Levemir, Chemical Structure, 2011 352
Figure 192: Type 2 Diabetes Therapeutics Market, Global, Levemir, Life Cycle Management Activities 353
Figure 193: Type 2 Diabetes Therapeutics Market, Global, Levemir Sales Forecast ($m), 2004–2020 354
Figure 194: Type 2 Diabetes Therapeutics Market, Global, Levemir, Market Share Analysis (%), 2011 355
Figure 195: Type 2 Diabetes Therapeutics Market, Global, Humalog Sales Forecast ($m), 2002–2020 358
Figure 196: Type 2 Diabetes Therapeutics Market, Global, Humalog, Market Share Analysis (%), 2011 359
Figure 197: Type 2 Diabetes Therapeutics Market, Global, Humulin Sales Forecast ($m), 2002-2020 361
Figure 198: Type 2 Diabetes Therapeutics Market, Global, Humulin, Market Share Analysis (%), 2011 362
Figure 199: Type 2 Diabetes Therapeutics Market, Global, Novolog Sales Forecast ($m), 2002-2020 365
Figure 200: Type 2 Diabetes Therapeutics Market, Global, Novolog, Market Share Analysis (%), 2011 366
Figure 201: Type 2 Diabetes Therapeutics Market, Global, Apidra, Sales Forecast ($m), 2004–2020 369
Figure 202: Type 2 Diabetes Therapeutics Market, Global, Apidra, Market Share Analysis (%), 2011 370
Figure 203: Type 2 Diabetes Therapeutics Market, Global, Welchol Sales Forecast ($m), 2008-2020 373
Figure 204: Type 2 Diabetes Therapeutics Market, Global, Nesnia Sales Forecast ($m), 2010-2020 377
Figure 205: Type 2 Diabetes Therapeutics Market, Global, Cycloset Sales Forecast ($m), 2010–2020 379
Figure 206: Type 2 Diabetes Therapeutics Market, Global, Tradjenta, Chemical Structure, 2011 380
Figure 207: Type 2 Diabetes Therapeutics Market, Global, Tradjenta Sales Forecast ($m), 2011–2020 384
Figure 208: Type 2 Diabetes Therapeutics Market, Global, Bydureon Sales Forecasts ($m), 2011–2020 388
Figure 209: Type 2 Diabetes Therapeutics Market, Global, Clinical Trials by Phase of Development (%), 2011 390
Figure 210: Type 2 Diabetes Therapeutics Market, Global, Pipeline by Mechanism of Action, 2011 391
Figure 211: Type 2 Diabetes Therapeutics Market Pipeline, Phase of Clinical Development, 2011 392
Figure 212: Type 2 Diabetes Therapeutics Market, Global, Technology Trends Analytic Framework of Pipeline Drugs, 2011 393
Figure 213: Type 2 Diabetes Therapeutics Market, Global, Technology Trends Description of Pipeline Drugs, 2011 393
Figure 214: Type 2 Diabetes Therapeutics Market, Global, Lixisenatide Sales Forecast ($m), 2013–2020 411
Figure 215: Type 2 Diabetes Therapeutics Market, Global, Syncria Sales Forecast ($m), 2014–2020 413
Figure 216: Type 2 Diabetes Therapeutics Market, Global, Degludec Sales Forecast ($m), 2013–2020 416
Figure 217: Type 2 Diabetes Therapeutics Market, Global, Dapagliflozin, Chemical Structure, 2011 416
Figure 218: Type 2 Diabetes Therapeutics Market, Global, Dapagliflozin Sales Forecast ($m), 2012–2020 419
Figure 219: Type 2 Diabetes Therapeutics Market, Global, Canagliflozin, Chemical Structure, 2011 419
Figure 220: Type 2 Diabetes Therapeutics Market, Global, Canagliflozin Sales Forecast ($m), 2013–2020 421
Figure 221: Type 2 Diabetes Therapeutics Market, Global, Empagliflozin Sales Forecast ($m), 2014–2020 424
Figure 222: Type 2 Diabetes Therapeutics Market, Global, Ipragliflozin, Chemical Structure, 2011 425
Figure 223: Type 2 Diabetes Therapeutics Market, Global, Ipragliflozin Sales Forecast ($m), 2014–2020 426
Figure 224: Type 2 Diabetes Therapeutics Market, Global, Aleglitazar, Chemical Structure, 2011 427
Figure 225: Type 2 Diabetes Therapeutics Market, Global, Aleglitazar Sales Forecast ($m), 2017–2020 428
Figure 226: Type 2 Diabetes Therapeutics Market, Global, Dulaglutide Sales Forecast ($m), 2014-2020 431
Figure 227: Type 2 Diabetes Therapeutics Market, Global, D-Tagatose, Chemical Structure, 2011 431
Figure 228: Type 2 Diabetes Therapeutics Market, Global, Naturlose Sales Forecast ($m), 2012–2020 433
Figure 229: Type 2 Diabetes Therapeutics Market, Global, Licensing Agreements by Phase of Development (%), 2011 443
Figure 230: Type 2 Diabetes Therapeutics Market, Global, Clinical Trials by Status, October 2011 448
Figure 231: Type 2 Diabetes Therapeutics Market, Global, Clinical Trials by Country, October 2011 449
Figure 232: Type 2 Diabetes Therapeutics Market, Global, Clinical Trials by Phase, October 2011 450
Figure 233: Type 2 Diabetes Therapeutics Market, Global, Clinical Trials by Sponsor Type, October 2011 451
Figure 234: Type 2 Diabetes Therapeutics Market, Global, Clinical Trials, Leading Sponsors, October 2011 452
Figure 235: Type 2 Diabetes Therapeutics Market, Global, Clinical Trials, Leading Company Sponsors, October 2011 453
Figure 236: Type 2 Diabetes Therapeutics Market, Global, Clinical Trials, Average Number of Patients Recruited, October 2011 454
Figure 237: Type 2 Diabetes, Global, Key Events Impacting the Future Market, 2011 455
Figure 238: Type 2 Diabetes Therapeutics Market, Global, Implications for Future Market Competition, 2011 457
Figure 239: Type 2 Diabetes, Clinical Pipeline by Company, 2011 459
Figure 240: Type 2 Diabetes, Novo Nordisk, SWOT Analysis 2011 460
Figure 241: Type 2 Diabetes, Amylin Pharmaceuticals, SWOT Analysis 2011 464
Figure 242: Type 2 Diabetes, Takeda Pharmaceuticals, SWOT Analysis 2011 468
Figure 243: Type 2 Diabetes, Boehringer Ingelheim, SWOT Analysis 2011 471
Figure 244: Type 2 Diabetes, Eli Lilly and Company, SWOT Analysis 2011 473
Figure 245: Type 2 Diabetes, GlaxoSmithKline, SWOT Analysis 2011 477
Figure 246: Type 2 Diabetes, Novartis AG., SWOT Analysis 2011 480
Figure 247: Type 2 Diabetes, Sanofi, SWOT Analysis 2011 483
Figure 248: Type 2 Diabetes, F.Hoffmann La Roche, SWOT Analysis 2011 486
Figure 249: Type 2 Diabetes, Bristol-Myers Squibb, SWOT Analysis 2011 488
Figure 250: Type 2 Diabetes, Johnson & Johnson, SWOT Analysis 2011 491
Figure 251: Type 2 Diabetes, Astellas, SWOT Analysis 2011 499
Figure 252: Type 2 Diabetes, Global, Key Data Inputs from KOL Interviews, April 2011 507
Figure 253: GlobalData  Market Forecasting Model 514

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *